{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:43:19Z","timestamp":1773153799071,"version":"3.50.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The family of multidrug resistance-associated proteins (MRPs) belongs to the superfamily of adenosine triphosphate-binding-cassette (ABC) transporters, which have the ability to function as outward pumps for chemotherapeutic drugs and therefore might be involved in drug resistance. In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32). All 5 genes were expressed with a great variability. Only MRP3 expression was associated with a significantly worse prognosis (P = .008). The median expression of MRP3 was 10-fold higher in T-ALL than in precursor B-ALL (P &amp;lt; .001) and 4-fold higher in male patients than in female patients (P &amp;lt; .001). The prognostic impact of MRP3 was independent of immunophenotype or sex. Higher levels of MRP3 were found in patients with a poor in vivo response to prednisone, but this could not be confirmed in an independent case-control study (40 patients) for prednisone response. In healthy donors, the median expression of MRP4 was 4-fold higher in bone marrow and 8-fold higher in CD34+ stem cells compared with peripheral blood (P = .002). Our results suggest that MRP3 is involved in drug resistance in childhood ALL. It therefore represents an interesting target to overcome multidrug resistance. High levels of MRP3 could possibly be the reason for the poorer prognosis of male patients or patients who have T-ALL. Similar to other members of the family of ABC transporters, MRP4 seems to be a marker for immature stem cells. (Blood. 2003;102:4493-4498)<\/jats:p>","DOI":"10.1182\/blood-2002-11-3461","type":"journal-article","created":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:32:50Z","timestamp":1056414770000},"page":"4493-4498","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype"],"prefix":"10.1182","volume":"102","author":[{"given":"Daniel","family":"Steinbach","sequence":"first","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susann","family":"Wittig","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Viehmann","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Mueller","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Haefer","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Zintl","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Sauerbrey","sequence":"additional","affiliation":[{"name":"From the University of Jena, Children's Hospital, Jena, Germany; the Hannover Medical School, Children's Hospital, Hannover, Germany; and the University of Giessen, Children's Hospital, Giessen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021221433121500_REF1","unstructured":"Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95: 3310-3322."},{"key":"2020021221433121500_REF2","doi-asserted-by":"crossref","unstructured":"Zintl F. Treatment of children with acute lymphoblastic leukemias in the German Democratic Republic until 1991. Klin Padiatr. 2001;213: 153-154.","DOI":"10.1055\/s-2001-16845"},{"key":"2020021221433121500_REF3","doi-asserted-by":"crossref","unstructured":"Sandlund JT, Harrison PL, Rivera G, et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood. 2002;100: 43-47.","DOI":"10.1182\/blood.V100.1.43"},{"key":"2020021221433121500_REF4","doi-asserted-by":"crossref","unstructured":"Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001;13: 463-469.","DOI":"10.1097\/00001622-200111000-00008"},{"key":"2020021221433121500_REF5","unstructured":"Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94: 1086-1099."},{"key":"2020021221433121500_","doi-asserted-by":"crossref","unstructured":"Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991;83: 708-712.","DOI":"10.1093\/jnci\/83.10.708"},{"key":"2020021221433121500_REF7","doi-asserted-by":"crossref","unstructured":"Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89: 3323-3329.","DOI":"10.1182\/blood.V89.9.3323"},{"key":"2020021221433121500_REF8","doi-asserted-by":"crossref","unstructured":"List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98: 3212-3220.","DOI":"10.1182\/blood.V98.12.3212"},{"key":"2020021221433121500_REF9","doi-asserted-by":"crossref","unstructured":"Tidefelt U, Liliemark J, Gruber A, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol. 2000;18: 1837-1844.","DOI":"10.1200\/JCO.2000.18.9.1837"},{"key":"2020021221433121500_REF10","doi-asserted-by":"crossref","unstructured":"Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer. 1994;70: 1144-1149.","DOI":"10.1038\/bjc.1994.462"},{"key":"2020021221433121500_REF11","doi-asserted-by":"crossref","unstructured":"Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol. 1999;105: 676-683.","DOI":"10.1046\/j.1365-2141.1999.01378.x"},{"key":"2020021221433121500_REF12","doi-asserted-by":"crossref","unstructured":"Kanerva J, Tiirikainen MI, Makipernaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol. 2001;18: 27-36.","DOI":"10.1080\/088800101750059837"},{"key":"2020021221433121500_REF13","doi-asserted-by":"crossref","unstructured":"den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein\/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91: 2092-2098.","DOI":"10.1182\/blood.V91.6.2092.2092_2092_2098"},{"key":"2020021221433121500_REF14","doi-asserted-by":"crossref","unstructured":"Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia. 2002;16: 1443-1447.","DOI":"10.1038\/sj.leu.2402541"},{"key":"2020021221433121500_REF15","doi-asserted-by":"crossref","unstructured":"Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2\/MXR\/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol. 2002;118: 147-150.","DOI":"10.1046\/j.1365-2141.2002.03550.x"},{"key":"2020021221433121500_REF16","doi-asserted-by":"crossref","unstructured":"Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92: 1295-1302.","DOI":"10.1093\/jnci\/92.16.1295"},{"key":"2020021221433121500_REF17","doi-asserted-by":"crossref","unstructured":"Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr. 2001;33: 493-501.","DOI":"10.1023\/A:1012827221844"},{"key":"2020021221433121500_REF18","doi-asserted-by":"crossref","unstructured":"van der Kolk DM, de Vries EG, Muller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma. 2002;43: 685-701.","DOI":"10.1080\/10428190290016773"},{"key":"2020021221433121500_REF19","doi-asserted-by":"crossref","unstructured":"Zintl F, Hafer R. Immunologic subclassification of acute lymphoblastic leukemia in childhood and prognosis (modified BFM protocol). Hamatol Bluttransfus. 1989;32: 109-112.","DOI":"10.1007\/978-3-642-74621-5_18"},{"key":"2020021221433121500_REF20","doi-asserted-by":"crossref","unstructured":"Zintl F, Malke H, Reimann M, et al. Results of acute lymphoblastic leukemia therapy in childhood: GDR-experiences 1981-1987. Hamatol Bluttransfus. 1990;33: 478-482.","DOI":"10.1007\/978-3-642-74643-7_86"},{"key":"2020021221433121500_REF21","doi-asserted-by":"crossref","unstructured":"Zintl F, Malke H, Reimann M, et al. Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991. Klin Padiatr. 1992;204: 221-229.","DOI":"10.1055\/s-2007-1025352"},{"key":"2020021221433121500_REF22","unstructured":"Schrappe M, Reiter A, Harbott J, et al. Improved risk-adapted treatment of childhood ALL with a new stratification system based on early response, genetics, age, and WBC: first interim analysis of trial ALL-BFM 95 [abstract]. Blood. 2001;98: 718a."},{"key":"2020021221433121500_REF23","doi-asserted-by":"crossref","unstructured":"Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic\/severe combined immunodeficient mice. Blood. 2000;95: 1237-1248.","DOI":"10.1182\/blood.V95.4.1237"},{"key":"2020021221433121500_REF24","doi-asserted-by":"crossref","unstructured":"Yoshida M, Suzuki T, Komiya T, et al. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int J Cancer. 2001;94: 432-437.","DOI":"10.1002\/ijc.1490"},{"key":"2020021221433121500_REF25","doi-asserted-by":"crossref","unstructured":"Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17: 818-824.","DOI":"10.1200\/JCO.1999.17.3.818"},{"key":"2020021221433121500_REF26","unstructured":"Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5 and SMRP in childhood AML. Clin Cancer Res. 2003;9: 1083-1086."},{"key":"2020021221433121500_REF27","unstructured":"Sirotnak FM, Wendel HG, Bornmann WG, et al. Co-administration of probenecid, an inhibitor of a cMOAT\/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res. 2000;6: 3705-3712."},{"key":"2020021221433121500_REF28","doi-asserted-by":"crossref","unstructured":"Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7: 1028-1034.","DOI":"10.1038\/nm0901-1028"},{"key":"2020021221433121500_REF29","doi-asserted-by":"crossref","unstructured":"Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99: 507-512.","DOI":"10.1182\/blood.V99.2.507"},{"key":"2020021221433121500_REF30","unstructured":"Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7: 1798-1804."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4493\/1693575\/h82403004493.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4493\/1693575\/h82403004493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T05:09:34Z","timestamp":1623128974000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/13\/4493\/17458\/The-multidrug-resistanceassociated-protein-3-MRP3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,15]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-11-3461","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,15]]}}}